# Neuralink

- Link: https://100xfounder.com/startup/neuralink/
- Published: 2024-01-01T00:00:00+05:30
- Author: Ishaan Vardhan

Neuralink is a neurotechnology company developing brain-computer interfaces: devices
implanted in the brain that read neural signals and turn them into commands for 
a computer or phone. It was founded in 2016, with Elon Musk among its founders. 
It also builds its own surgical robot to place the implant.

Its first product, called Telepathy, is aimed at people with paralysis, letting 
them move a cursor and type by thought. In a post on 28 January 2026 marking two
years of human trials, Neuralink said 21 participants, whom it calls Neuralnauts,
were enrolled in its trials worldwide, that the trial had grown from three participants
in 2024 to several a month in 2025, and that it had seen no serious device-related
adverse events. It said some participants type at up to 40 words a minute, and that
a separate trial called VOICE aims to restore speech. These are the company’s own
figures and have not been independently verified.

A second device, Blindsight, is meant to restore some vision to people who have 
lost their sight. The US Food and Drug Administration gave it a Breakthrough Device
designation in 2024, and in May 2025 Neuralink received another for restoring communication
to people with severe speech impairment, according to reporting on its funding.

On 2 June 2025 Neuralink announced a $650 million Series E. Investors included ARK
Invest, Founders Fund, Sequoia Capital and Thrive Capital, TechCrunch reported, 
and Semafor put the pre-money valuation at about $9 billion.

Neuralink has no product on sale and no published price. Its devices are available
only to people enrolled in its clinical trials.

_This page is research, not a review: Neuralink has no product we could try. It 
brings together Neuralink’s own website and the reporting linked under Sources, 
and says where each fact comes from._